Brainstorm Cell Therapeutics reported results from a multicenter, open-label phase 2 trial of NurOwn in progressive multiple sclerosis. Results showed a good safety and tolerability profile,…
Sanofi presented data from a Phase 2b long-term extension study (LTS) evaluating tolebrutinib in patients with relapsing forms of multiple sclerosis (RMS). The results showed that after 48…
In a deal worth nearly $1 billion if all milestones are met, one of the world’s largest biotech companies, Cambridge, MA-based Biogen Inc. (Nasdaq: BIIB) licensed…
Article 1: Are the current mRNA-based vaccines authorized for emergency use by the U.S. Food and Drug Administration (FDA) safe for those diagnosed with multiple…
Are the current mRNA-based vaccines authorized for emergency use by the U.S. Food and Drug Administration (FDA) safe for those diagnosed with multiple sclerosis (MS)?…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
